

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

TRIPEP.023AUS2

APPLICATION NO.

09/929,955

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT

Sallberg et al.

FILING DATE

August 15, 2001

GROUP

1648

SHEET 1 OF 3

SEP 10 2003

TECH CENTER 1601/2900

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BCL	1.	4,950,647	08/21/90	Robins et al.	-	-	
	2.	5,350,671	09/27/94	Houghton et al.	-	-	
	3.	5,372,928	12/13/94	Miyamura et al.	-	-	
	4.	5,670,152	09/23/97	Weiner et al.	-	-	
	5.	5,670,153	09/23/97	Weiner et al.	-	-	
	6.	5,683,864	11/04/97	Houghton et al.	-	-	
	7.	5,712,145	01/27/98	Houghton et al.	-	-	
	8.	5,728,520	03/17/98	Weiner et al.	-	-	
	9.	5,756,312	03/26/98	Weiner et al.	-	-	
	10	5,767,097	06/16/98	Tam	-	-	
	11	5,856,437	01/05/99	Miyamura et al.	-	-	
	12	5,871,903	02/16/99	Miyamura et al.	-	-	
	13	5,942,234	08/24/99	Ralston et al.	-	-	
	14	5,989,905	11/23/99	Houghton et al.	-	-	
	15	6,060,068	05/09/00	Doyle et al.	-	-	
	16	6,063,772	05/16/00	Tam	-	-	
	17	6,071,693	06/06/00	Cha et al.	-	-	
	18	6,190,864	02/20/01	Cha et al.	-	-	
	19	6,194,140	02/27/01	Houghton et al.	-	-	
	20	6,214,583	04/10/01	Cha et al.	-	-	
	21	6,541,011	04/01/03	Punnonen et al.	-	-	
	22	6,555,114	04/29/03	Leroux-Roels et al.	-	-	
	23	2003/0044774	03/06/03	Valenzuela et al.	-	-	
	24	2003/0064360	04/03/03	Maertens et al.	-	-	

EXAMINER

Baoguan L.

DATE CONSIDERED

02/20/2004

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


RECEIVED
SEP 10 2003
TECH CENTER 1000/2000

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. TRIPEP.023AUS2	APPLICATION NO. 09/929,955
	APPLICANT Sallberg et al.	
	FILING DATE August 15, 2001	GROUP 1648

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BOL	25	WO 96/28162	09/19/96	WIPO	-	-		
	26	WO 97/26883	07/31/97	WIPO	-	-		
	27	WO 98/16184	04/23/98	WIPO	-	-		
	28	WO 98/16186	04/23/98	WIPO	-	-		
	29	WO 98/30223	07/16/98	WIPO	-	-		
	30	WO 00/44388	08/03/00	WIPO	-	-		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
BOL	31	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).
	32	Abregnani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).
	33	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).
	34	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 (date unknown).
	35	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).
	36	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model", <i>Journal of Immunology</i> , 161:4917-4923 (1998).
	37	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).
	38	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).
	39	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine", <i>Clin Liver Dis</i> , 3(4):901-915 (1999).
	40	Kumar et al., "Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation," <i>Journal of Viral Hepatitis</i> , 7:459-465 (2000).
	41	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>International Journal of Dermatology</i> , 34(9):597-606 (1995).
	42	Proust B. et al., "Two Successive Hepatitis C Virus Infections in an Intravenous Drug User," <i>Journal of Clinical Microbiology</i> , 38(8):3125-3127 (2000).
	43	Ramasamy et al., "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity," <i>Journal of Medicinal Chemistry</i> , 43(5):1019-1028 (2000).
	44	Schulof R. S., "Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV-Infected Homosexual Men," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 3(5):485-492 (1990).

EXAMINER	Bao Qun Li	DATE CONSIDERED	02/20/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

 <p>FORM PT 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>SEP 08 2003</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. TRIEP.023AUS2	APPLICATION NO. 09/929,955
	APPLICANT Salberg et al.	
	FILING DATE August 15, 2001	GROUP 1648

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>Daogel</i>	45 Spector et al., "The Antiviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker," <i>Journal of Infectious Diseases</i> , 159(5):822-828 (1989).
<i>V</i>	46 Tam et al., "Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile," <i>Journal of Hepatology</i> , 30(3):376-382 (1999) (ABSTRACT).
<i>V</i>	47 Tam et al., "The Immunomodulatory effects of ribavirin: Recent findings," <i>International Antiviral News</i> , 7/6:99 - 100 (1999).
<i>V</i>	48 Walsh et al., "Update on chronic viral hepatitis", <i>Postgrad Medical Journal</i> , 77(910):498-505 (2001).
<i>V</i>	49 Wang et al., "Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3-d]-4-pyrimidone Nucleosides," <i>J. Med. Chem.</i> , 43(13):2566-2574 (2000).
<i>V</i>	50 http://www.msi.com/life/products/cerius2/modules/analogbuilder.html , C2Analog Builder, July 6, 2000.
<i>V</i>	51 Zhang et al., "Interferon- α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy," <i>The Journal of Infectious Diseases</i> , 175:1294-1301 (1997).

S:\DOCS\IESF\ESF-7006.DOC
082203

EXAMINER <i>Daogun Li</i>	DATE CONSIDERED <i>02/20/2004</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	